- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| JUPITER NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Noble Financial Group, Inc.: Jupiter Neurosciences to Participate in NobleCon21 | 325 | Newsfile | Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based therapeutic... ► Artikel lesen | |
| 26.11.25 | JUPITER NEUROSCIENCES, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 14.11.25 | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | FDA clears Jupiter Neurosciences' IND for Parkinson's drug trial | 1 | Investing.com | ||
| 27.10.25 | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.10.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing | 1 | GlobeNewswire (USA) | ||
| 19.08.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia Brand Ambassador | 5 | GlobeNewswire (USA) | ||
| 19.08.25 | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08.25 | JUPITER NEUROSCIENCES, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| 23.07.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Highlights Critical Advancement of JOTROL Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science | 223 | GlobeNewswire (Europe) | Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company")... ► Artikel lesen | |
| 10.07.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement | 253 | GlobeNewswire (Europe) | Nasdaq compliance follows positive upward trend in Company's Stock Price Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company")... ► Artikel lesen | |
| 12.06.25 | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | 967 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| 09.06.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Launches Nugevia: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science | 1.486 | GlobeNewswire (Europe) | First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences... ► Artikel lesen | |
| 07.03.25 | RedChip Companies, Inc.: Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 512 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / March 7, 2025 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Jupiter Neurosciences, Inc. (Nasdaq:JUNS) on the RedChip... ► Artikel lesen | |
| 30.01.25 | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial | 318 | GlobeNewswire (Europe) | Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based... ► Artikel lesen | |
| 24.01.25 | Pre-market Movers: Allurion Technologies, Nvni Group, Dogwood Therapeutics, Jupiter Neurosciences, CTRL Group Limited | 1.386 | AFX News | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 297%... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TONIX PHARMACEUTICALS | 15,900 | +2,58 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) | Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product of TNX-4800 (anti-Borrelia... ► Artikel lesen | |
| BAYER | 43,150 | +1,09 % | Bayer: Gipfelsturm in dünner Luft | Seit Anfang Dezember nimmt die Bayer-Aktie eine Charthürde nach der anderen - und das gestern sogar gegen den Markttrend. Jahrelang stieg der DAX, aber Bayer blieb zurück. Jetzt hängt die Aktie den... ► Artikel lesen | |
| NOVO NORDISK | 51,53 | +1,40 % | Opening Bell: Goldman Sachs, Morgan Stanley, TSMC + Rally bei Chipausrüstern, Novo Nordisk, BYD | An der Wall Street überwog am Mittwoch die Vorsicht. Der Dow Jones gab nach anfänglichen Verlusten nur leicht nach und schloss 0,09 Prozent tiefer. Der Nasdaq Composite blieb deutlicher unter Druck... ► Artikel lesen | |
| HARROW | 47,120 | -1,26 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| MERCK KGAA | 126,40 | +1,85 % | Déjà-vu im Januar: Diese Biotech-Aktie steht wieder am 2025er Aufwärtstrend - und der Markt könnte erneut falsch liegen | ||
| ASTRIA THERAPEUTICS | 12,490 | +0,40 % | Astria Therapeutics, Inc.: Stockholders Vote to Approve Acquisition by BioCryst Pharmaceuticals, Inc. | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,355 | -3,59 % | Aquestive Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| MILESTONE PHARMACEUTICALS | 2,010 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| PFIZER | 22,285 | +0,54 % | Pfizer: Die beste Pharma-Aktie 2026? | Die Aktie von Pfizer gewinnt wieder an Dynamik und rückt damit verstärkt in das Blickfeld langfristig orientierter Anleger. Angesichts einer attraktiven Bewertung, operativer Fortschritte und einer... ► Artikel lesen | |
| COMPASS PATHWAYS | 6,050 | +0,83 % | MDMA-Produktion 2026: Bioxyne greift mit neuem GMP-Werk an -Konkurrenz für Compass Pathways und MindMed | ||
| LIPOCINE | 9,740 | -1,81 % | Lipocine Inc.: Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | SALT LAKE CITY, Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 85,92 | +3,52 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| SANOFI | 79,11 | -0,54 % | GOLDMAN SACHS stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Sanofi von 95 auf 90 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Analyst James Quigley passte sein... ► Artikel lesen | |
| LB PHARMACEUTICALS | 21,650 | +0,42 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| ELI LILLY | 927,10 | +0,46 % | Nicht Novo, nicht Lilly - das ist der nächste Abnehm-Profiteur | Der Boom um Abnehmspritzen und neue Wirkstoffklassen hat einen der größten Wachstumsmärkte der globalen Gesundheitsindustrie geschaffen. GLP-1-Wirkstoffe verändern die Behandlung von Übergewicht grundlegend... ► Artikel lesen |
Das Unternehmen JUPITER NEUROSCIENCES INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,029 (+3,22 %) liegt der Kurs bei 0,929 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JUPITER NEUROSCIENCES INC finden Sie auf Wallstreet Online.